UAE reveals 86% effiacy for Sinopharm’s COVID-19 vaccine
The Health Ministry of the United Arab Emirates has unveiled the first known efficacy data for the COVID-19 vaccine candidate from Chinese state-owned pharmaceutical firm Sinopharm, painting a similarly strong picture to those seen from other vaccine manufacturers including Moderna and Pfizer/BioNTech in recent weeks.
Phase 3 trials for the therapy kicked off in July this year, comprising 31,000 participants of 125 different nationalities. According to interim analysis of the trials, the vaccine showed an efficacy rate of 86%, with a “99% seroconversion rate of neutralising antibody and 100% effectiveness in preventing moderate and severe cases of the disease.”
This is the first publication of any efficacy findings associated with Sinopharm’s vaccine, and while it paints a promising picture, details were thin; the analysis identified “no serious safety concerns” with the candidate, but did not reveal information on the prevalence of side-effects or how many participants received either the vaccine or a control therapy.
The therapy has been approved for emergency use in the UAE since September for frontline healthcare staff, and nearly 100,000 UAE citizens have already received it on a voluntary basis.
GSK announced positive results from its phase 3 trial which assessed the immune response and …
GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological …